Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous Blinatumomab and Revumenib in KMT2A-rearranged ALL
NCT07283640Phase 1Not yet recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2026
- Primary completion
- Aug 2029
- Modality
- Antibody Conjugates, scFv Fragments, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of blinatumomab and revumenib in acute lymphoblastic leukemia (ALL) (2 cohorts), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Safety and Adverse Events at 1 year, Overall Response Rate at 1 year and 1 more. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
blinatumomabrevumenib
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT07283640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07283640.